HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICEATM/ ICCVAM

This article was originally published in The Rose Sheet

Executive Summary

Public comment is requested on the development of a five-year plan for the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) and the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM). In a Nov. 13 Federal Register notice, the National Institute of Environmental & Health Sciences solicits input on the highest priority areas for the development of alternatives to the use of animals in safety testing. The public is asked to consider the R&D and validation activities likely to have the greatest impact on alternative testing within the next five years, as well as appropriate measures for evaluating the progress of the alternative methods initiative. Comments should be submitted through the NICEATM/ICCVAM Web site by Dec. 31, 2006. Comments will also be accepted at the Nov. 30 meeting of the Scientific Advisory Committee on Alternative Toxicological Methods in Research Triangle Park, N.C...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS014360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel